Google's venture arm backs US AI health tool at $6b valuation

OpenEvidence, a Miami-based AI startup, has raised US$200 million in new funding, boosting its valuation to US$6 billion.

The round was led by GV, Google’s venture arm, with participation from Sequoia, Kleiner Perkins, Blackstone, Thrive Capital, Coatue, Bond, and Craft.

The company offers an AI-powered search tool for doctors and claims to serve 40% of US physicians.

Its platform now handles 16.5 million monthly clinical consultations, up from 10 million in July.

The software is free for verified doctors and generates revenue through ads.

In September, OpenEvidence acquired Amaro, an AI ad firm, to enhance its ad capabilities.

🔗 Source: Forbes

🧠 Food for thought

Implications, context, and why it matters.

OpenEvidence meets Health Insurance Portability and Accountability Act (HIPAA) rules as of April 2025 1. Handling of physician-submitted patient data remains unclear when doctors share observations on rare or complex cases.
Terms of Use say users must keep content within the law, including HIPAA rules 2, and a Business Associate Agreement (BAA) applies when a covered entity accepts Terms 3. The process for BAA coverage for physicians on the free tool, the method for de-identifying submissions, and whether any decision support features trigger Food and Drug Administration (FDA) medical device oversight remain unspecified.
These regulatory gaps affect scale. If doctors face risk when sharing observations or if FDA clearance becomes necessary, OpenEvidence’s path to medical superintelligence could slow or require costly compliance.

The tool reaches 40% of U.S. physicians. Its ad-supported model tracks a shift in how pharma reaches doctors. Healthcare professional (HCP) marketing hit an estimated $20 billion in 2016 4, with healthcare advertising projected at $67.87 billion by 2033 5.
Ad tech and analytics firms can build healthcare tools. Options include contextual targeting that fits privacy rules 6 and real-time performance measurement 7 that pharma buyers want.
Vendors offering HIPAA-compliant verification, brand-safety checks, and National Provider Identifier (NPI)-based targeting can benefit. NPI is a unique identifier assigned to U.S. clinicians. Nine in ten healthcare and pharma marketers plan to boost digital video and social spending 8.